Engineering of new bio-materials and
-pharmaceuticals
Acute ischemic stroke is one of the leading causes of death or disability worldwide and according to World Health Organization, acute stroke will remain the second most important cause of death in 2030. The main objectives of the project Engineering of new biomaterials and biopharmaceuticals for the diagnosis and treatment of the cerebrovascular and neurodegenerative diseases – INBIO addresses the complex issues thanks to the unique expertise and long-term experience of academic, clinical and industrial partners involved. Long-term interdisciplinary and intersectoral partnerships is estasblished among four academic/clinical research groups and two industrial partners -Loschmidt Laboratories, FNUSA-ICRC, Institute of Biophysics of the Czech Academy of Sciences, Institute of Scientific Instruments of the Czech Academy of Sciences, Biovendor and Contipro. Students are educated jointly by the experts from academia and industry, which are providing them with a better understanding of the needs and working habits in R&D accross the sectors. Collaborations with leading European research institutions and international companies is also established.
We are providing high-level training to young scientists working at the interface of scientific disciplines and across sectors. The consortium alumni is also able to create innovative solutions to difficult practical problems thank to a long-term collaboration in R&D academical teams and companies. Overall, the project contributes towards the exploration of costly state-of-the-art instruments and also stimulates interactions of academic and industrial partners which is in line with the priorities defined by the Regional Innovation Strategy.
Principal Investigator: prof. Mgr. Jiří Damborský, Ph.D.
Financed by: Operational program Research, Development and Education Grant of the Ministry of Education, Youth and Sports of the Czech Republic
Duration: 01.09.2019 – 31.12.2022